What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Amgen Inc.'s unaudited financial results for the first quarter ended March 31, 2013, and to provide its financial position as of that date. It includes a press release detailing these results and the company's use of non-GAAP financial measures.

Why does Amgen use non-GAAP financial measures in its reporting?

Amgen uses non-GAAP financial measures to offer investors supplementary information that they believe provides a clearer and more comparable view of the company's operational performance and profitability. These measures exclude certain items such as non-cash amortization, stock-based compensation, acquisition-related expenses, and other one-time or non-recurring costs.

What types of expenses are typically excluded in Amgen's non-GAAP reporting?

Typical exclusions in Amgen's non-GAAP reporting include the non-cash amortization of product technology rights and intangible assets acquired in business combinations, the impact of expensing stock options, acquisition-related expenses, contingent consideration costs, legal expenses, non-cash interest expense on convertible notes, and certain tax effects. The company also reports Free Cash Flow (FCF) as a non-GAAP liquidity measure.

Where can I find the detailed financial results and reconciliations?

The detailed financial results and reconciliations between GAAP and non-GAAP financial measures for the first quarter of 2013 and 2012 are available in the press release attached as Exhibit 99.1 to this 8-K filing.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. filed an 8-K on April 23, 2013, to report its unaudited financial results for the first quarter ended March 31, 2013, alongside its financial position as of the same date. The filing primarily consists of a press release detailing these results and the company's use of non-GAAP financial measures to provide supplemental insights for investors. Amgen utilizes these adjusted figures to offer a clearer view of its operational performance by excluding certain non-cash items, acquisition-related expenses, stock-based compensation impacts, legal expenses, contingent consideration costs, and tax effects. The company emphasizes that these non-GAAP measures are not a substitute for GAAP reporting but are intended to facilitate a more comprehensive analysis of its profitability and operational efficiency. They believe that by excluding items like the amortization of acquired intangible assets, they can better compare the performance of acquired intellectual property to internally developed assets. This approach aims to provide investors with a more consistent and comparable view of the company's underlying business performance over time.

Key Highlights

1Amgen Inc. announced its unaudited financial results for the first quarter ended March 31, 2013.
2The company utilizes non-GAAP financial measures, excluding specific items like amortization of acquired intangible assets, stock-based compensation, acquisition-related expenses, legal costs, and contingent consideration, to present supplemental performance data.
3Amgen believes these non-GAAP measures provide investors with enhanced insights into its operational performance and profitability.
4The press release attached as Exhibit 99.1 contains detailed reconciliations between GAAP and non-GAAP financial figures for the periods ending March 31, 2013, and March 31, 2012.
5The filing also reports Free Cash Flow (FCF), a non-GAAP measure, calculated by subtracting capital expenditures from cash flow from operations, to provide a further measure of liquidity.
6Amgen's Chief Financial Officer, Jonathan M. Peacock, signed the report.

AMGEN INC 8-K Report, Financial Results (Apr 23, 2013)

Summary

Key Highlights

Frequently Asked Questions